HomeCompareBXEAX vs MRK

BXEAX vs MRK: Dividend Comparison 2026

BXEAX yields 99.98% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BXEAX wins by $3.84M in total portfolio value
10 years
BXEAX
BXEAX
● Live price
99.98%
Share price
$7.60
Annual div
$7.60
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.89M
Annual income
$1,311,551.55
Full BXEAX calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — BXEAX vs MRK

📍 BXEAX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBXEAXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BXEAX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BXEAX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BXEAX
Annual income on $10K today (after 15% tax)
$8,498.10/yr
After 10yr DRIP, annual income (after tax)
$1,114,818.82/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, BXEAX beats the other by $1,106,490.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BXEAX + MRK for your $10,000?

BXEAX: 50%MRK: 50%
100% MRK50/50100% BXEAX
Portfolio after 10yr
$1.97M
Annual income
$660,674.85/yr
Blended yield
33.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

BXEAX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BXEAX buys
0
MRK buys
0
No recent congressional trades found for BXEAX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBXEAXMRK
Forward yield99.98%2.76%
Annual dividend / share$7.60$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$3.89M$56.8K
Annual income after 10y$1,311,551.55$9,798.13
Total dividends collected$3.48M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BXEAX vs MRK ($10,000, DRIP)

YearBXEAX PortfolioBXEAX Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$20,698$9,997.76$11,206$366.19+$9.5KBXEAX
2$41,486$19,339.38$12,650$502.35+$28.8KBXEAX
3$80,617$36,227.36$14,407$694.19+$66.2KBXEAX
4$152,054$65,793.07$16,585$967.82+$135.5KBXEAX
5$278,672$115,975.06$19,342$1,363.89+$259.3KBXEAX
6$496,825$198,645.19$22,913$1,947.19+$473.9KBXEAX
7$862,584$330,981.26$27,662$2,823.89+$834.9KBXEAX
8$1,460,018$537,053.66$34,159$4,173.35+$1.43MBXEAX
9$2,411,773$849,553.87$43,337$6,308.80+$2.37MBXEAX
10$3,892,149$1,311,551.55$56,776$9,798.13+$3.84MBXEAX

BXEAX vs MRK: Complete Analysis 2026

BXEAXStock

The fund will invest at least 80% of its net assets (plus the amount of any borrowings for investment purposes) in (i) securities denominated in currencies of the emerging market countries, (ii) fixed income securities or debt instruments issued by emerging market entities or sovereign nations, and/or (iii) debt instruments denominated in or based on the currencies, interest rates, or issues of emerging market countries.

Full BXEAX Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this BXEAX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BXEAX vs SCHDBXEAX vs JEPIBXEAX vs OBXEAX vs KOBXEAX vs MAINBXEAX vs JNJBXEAX vs ABBVBXEAX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.